In the decades-long war against disease, pharmaceutical companies have learned to build drugs like locksmiths—designing compounds that fit neatly into molecular pockets, disabling enzymes and receptors with surgical precision. But not every biological lock comes with a keyhole. Protein–protein interactions, or PPIs, often involve broad, flat, and shifting surfaces that refuse to conform to conventional small molecule designs. This has led generations of drug developers to write off PPIs as “undruggable.”
That narrative is now collapsing. A growing number of biotech firms are proving that with the right structural scaffolds, deep molecular insight, and real-time biological feedback, even the slipperiest intracellular targets can be brought under control. From oncology to fibrotic disease, PPIs are emerging not just as viable drug targets but as one of the most competitive frontiers in modern therapeutics. And while platforms vary, the common thread is a return to chemistry—not as a supporting actor, but as the main protagonist.
How next-gen PPIs are enabling oral drugs against intracellular targets
The central challenge in targeting PPIs lies in their architecture. Unlike kinases or G protein-coupled receptors, PPIs lack catalytic pockets or transmembrane grooves. Instead, they rely on conformationally complex interfaces that shift depending on cellular context. These interactions often drive essential processes like DNA repair, transcriptional control, and apoptotic signaling—making them biologically powerful, but chemically elusive.
What has changed is the toolkit. Companies like PRISM BioLab Co. Ltd. have developed structurally defined mimetics that replicate the three-dimensional topology of alpha-helices and beta-turns—motifs commonly found at the interface of protein complexes. PRISM’s PepMetics platform, for example, uses proprietary scaffolds to create orally bioavailable compounds that can enter the cell and engage targets previously thought inaccessible to small molecules.
In oncology, this opens up a new class of intervention points. Consider the interaction between β-catenin and CBP, a known driver of transcriptional dysregulation in cancer. PRISM has licensed a PepMetics inhibitor of this interaction to Eisai Co., Ltd., which is now progressing through clinical development. Another compound targeting a separate PPI axis is under license to Ohara Pharmaceuticals Co., Ltd. for fibrotic liver disease, where it aims to disrupt pathological fibroblast activation.
The advantage of this approach is twofold. First, it bypasses the need for biologics, which are often unable to penetrate the cell membrane. Second, it offers the potential for more nuanced control, selectively interfering with specific protein interfaces without broadly inhibiting entire protein families. The result is a drug that works more like a scalpel than a hammer—precise, adaptable, and potentially safer.
Why investors are betting on chemically structured mimetics over peptides
While peptide-based drugs have made strides in targeting intracellular functions, their inherent limitations are well known. Poor oral bioavailability, rapid degradation, and delivery constraints continue to limit their utility outside of highly specialized indications. This has opened the door for structured small molecule mimetics that retain the binding specificity of peptides but shed their pharmacokinetic liabilities.
Investors have taken note. Frontier Medicines, a company developing covalent ligands to disrupt PPI networks, has raised hundreds of millions to advance its discovery engine. Nurix Therapeutics, meanwhile, is using its DELigase platform to identify degraders that disrupt PPI-mediated protein stability. And VantAI, a New York-based firm, is applying AI to scaffold design, aiming to replicate PPI motifs with high-fidelity molecular surrogates.
What unites these approaches is the belief that PPIs are not undruggable, merely misunderstood. The key is not to force conventional chemistries into unsuitable environments, but to build new scaffolds that are purpose-designed for PPI engagement. Many of these platforms now incorporate real-time structural feedback, machine learning refinement, and phenotypic screening in complex cellular models.
For venture capital firms and strategic investors, the appeal is simple. PPI targets are deeply validated in human biology but have few or no approved therapies. That creates a wide-open commercial runway for first-in-class and best-in-class drugs, particularly in competitive areas like oncology, where differentiation is hard to achieve.
What clinical endpoints will determine success in PPI-based therapies
The ultimate test for these platforms will not be their elegance in a lab but their ability to deliver in patients. For PPI inhibitors, this raises unique questions about endpoint selection, biomarker validation, and translational relevance. Because many PPI targets are involved in transcriptional or regulatory pathways, the clinical effects may take longer to materialize than with direct enzyme inhibitors.
In cancer, progression-free survival and objective response rates remain key benchmarks, but PPI-targeting agents may also need to demonstrate modulation of downstream gene expression or pathway reactivation. For example, a β-catenin–CBP inhibitor might be expected to reduce oncogene transcription or restore immune cell infiltration in tumors. These effects can be tracked through RNA sequencing, immunohistochemistry, or circulating biomarkers—but will need to be validated prospectively.
In fibrosis, the story is different. Here, histological changes, serum fibrosis markers, and organ function are likely to play a larger role. The challenge is that fibrotic diseases often progress slowly, which complicates trial design. Early signals of activity may come from imaging studies or reductions in biomarkers like TGF-β or collagen deposition. Ultimately, however, hard clinical outcomes such as liver stiffness or pulmonary function will determine success.
Regulators are also watching closely. The U.S. Food and Drug Administration has shown a willingness to engage with novel mechanisms, but expects mechanistic clarity and strong pharmacodynamic evidence in early-stage trials. For PPI inhibitors, this means linking target engagement to downstream effects with greater rigor than for more conventional drugs.
Why PRISM, Frontier, Nurix, and others are defining the next chapter in intracellular drug development
What unites companies like PRISM BioLab, Frontier Medicines, and Nurix Therapeutics is a belief that the boundaries of druggability are not fixed but fluid. PRISM’s clinical progress offers proof-of-concept that PPI mimetics can be formulated, dosed, and advanced through trials in both oncology and fibrotic disease. Frontier’s covalent chemistry strategy and Nurix’s bifunctional degrader approach represent different but equally bold bets on unlocking intracellular complexity.
Beyond technology, these companies are redefining how drug discovery is organized. Rather than chase ever-larger datasets or repurpose known inhibitors, they are building platforms that generate novel chemistry and validate it in real-world biological systems. The shift is not just about tools but about epistemology—a rethinking of how targets are selected, how compounds are optimized, and how success is measured.
For the broader industry, the implications are significant. If even a handful of these platforms succeed, it will open vast new therapeutic territory across dozens of diseases. Proteins once dismissed as undruggable may become routine components of pharmaceutical pipelines. Small molecules, long feared to be losing ground to biologics, could stage a resurgence powered by structural ingenuity and computational foresight.
What comes next for PPI inhibitors in cancer and fibrosis
As the first wave of PPI-targeting drugs moves through the clinic, several inflection points are approaching. Clinical readouts from PRISM BioLab’s partnered programs with Eisai and Ohara will be watched for signs of efficacy and safety. Likewise, any preclinical-to-clinic transitions from Frontier Medicines or Nurix Therapeutics will help validate their respective platforms.
Collaborations are likely to increase as large pharmaceutical companies look to bolt on these capabilities. Already, partnerships around degrader technologies and scaffold design have begun to proliferate, with companies seeking to gain early access to novel PPI-targeting pipelines.
From a regulatory and payer perspective, these therapies will need to prove not just novelty but value. Clear biomarker strategies, robust manufacturing protocols, and strong safety profiles will be essential. But if these hurdles can be cleared, the prize is considerable—a new generation of drugs that finally reaches the targets that matter most.
The undruggable no more? Inside the new wave of PPI inhibitors in cancer and fibrosis added by Venkatesh B on
View all posts by Venkatesh B →